nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB4—gallbladder cancer	0.00523	0.00523	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—ERBB3—gallbladder cancer	0.00518	0.00518	CbGpPWpGaD
Temsirolimus—MTOR—CXCR3-mediated signaling events—HRAS—gallbladder cancer	0.00516	0.00516	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB4—gallbladder cancer	0.00499	0.00499	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—ERBB4—gallbladder cancer	0.00499	0.00499	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—ERBB4—gallbladder cancer	0.00499	0.00499	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—ERBB3—gallbladder cancer	0.00495	0.00495	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—ERBB4—gallbladder cancer	0.00495	0.00495	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—ERBB4—gallbladder cancer	0.0049	0.0049	CbGpPWpGaD
Temsirolimus—MTOR—LKB1 signaling events—TP53—gallbladder cancer	0.00488	0.00488	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—ERBB4—gallbladder cancer	0.00488	0.00488	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—ERBB3—gallbladder cancer	0.00487	0.00487	CbGpPWpGaD
Temsirolimus—MTOR—ErbB2/ErbB3 signaling events—HRAS—gallbladder cancer	0.00485	0.00485	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—EGFR—gallbladder cancer	0.00485	0.00485	CbGpPWpGaD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—ERBB2—gallbladder cancer	0.00482	0.00482	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BCL2—gallbladder cancer	0.00466	0.00466	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—ERBB3—gallbladder cancer	0.00465	0.00465	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—ERBB3—gallbladder cancer	0.00463	0.00463	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—ERBB4—gallbladder cancer	0.00462	0.00462	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—EGFR—gallbladder cancer	0.00461	0.00461	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—ERBB3—gallbladder cancer	0.00461	0.00461	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—ERBB3—gallbladder cancer	0.00459	0.00459	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—KRAS—gallbladder cancer	0.00458	0.00458	CbGpPWpGaD
Temsirolimus—MTOR—mTOR signaling pathway—NRAS—gallbladder cancer	0.00453	0.00453	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—ERBB2—gallbladder cancer	0.00453	0.00453	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB3—gallbladder cancer	0.00452	0.00452	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB4—gallbladder cancer	0.00442	0.00442	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—ERBB2—gallbladder cancer	0.00434	0.00434	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—ERBB3—gallbladder cancer	0.00431	0.00431	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB3—gallbladder cancer	0.00431	0.00431	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—ERBB3—gallbladder cancer	0.00431	0.00431	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—ERBB3—gallbladder cancer	0.00428	0.00428	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—ERBB3—gallbladder cancer	0.00424	0.00424	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—ERBB2—gallbladder cancer	0.00424	0.00424	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—BCL2—gallbladder cancer	0.00423	0.00423	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—ERBB3—gallbladder cancer	0.00422	0.00422	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—ERBB2—gallbladder cancer	0.0042	0.0042	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—ERBB2—gallbladder cancer	0.00411	0.00411	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—TP53—gallbladder cancer	0.00407	0.00407	CbGpPWpGaD
Temsirolimus—MTOR—Regulation of Telomerase—EGFR—gallbladder cancer	0.00403	0.00403	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—ERBB3—gallbladder cancer	0.00399	0.00399	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—KRAS—gallbladder cancer	0.00395	0.00395	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KEAP1—gallbladder cancer	0.00392	0.00392	CbGpPWpGaD
Temsirolimus—MTOR—mTOR signaling pathway—KRAS—gallbladder cancer	0.0039	0.0039	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—HRAS—gallbladder cancer	0.00389	0.00389	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—TP53—gallbladder cancer	0.00387	0.00387	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB3—gallbladder cancer	0.00382	0.00382	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—NRAS—gallbladder cancer	0.0037	0.0037	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—NRAS—gallbladder cancer	0.0036	0.0036	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—NRAS—gallbladder cancer	0.00357	0.00357	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—gallbladder cancer	0.00351	0.00351	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—NRAS—gallbladder cancer	0.00347	0.00347	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—NRAS—gallbladder cancer	0.00347	0.00347	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—ERBB4—gallbladder cancer	0.0034	0.0034	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—gallbladder cancer	0.00336	0.00336	CbGpPWpGaD
Temsirolimus—MTOR—AMPK Signaling—TP53—gallbladder cancer	0.00335	0.00335	CbGpPWpGaD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—gallbladder cancer	0.00334	0.00334	CbGpPWpGaD
Temsirolimus—MTOR—TSH signaling pathway—HRAS—gallbladder cancer	0.00332	0.00332	CbGpPWpGaD
Temsirolimus—MTOR—mTOR signaling pathway—HRAS—gallbladder cancer	0.00332	0.00332	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—ERBB2—gallbladder cancer	0.00325	0.00325	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—KRAS—gallbladder cancer	0.00319	0.00319	CbGpPWpGaD
Temsirolimus—MTOR—CDC42 signaling events—HRAS—gallbladder cancer	0.00316	0.00316	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—BCL2—gallbladder cancer	0.00316	0.00316	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	0.00314	0.00314	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—NRAS—gallbladder cancer	0.00313	0.00313	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—ERBB2—gallbladder cancer	0.0031	0.0031	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—KRAS—gallbladder cancer	0.0031	0.0031	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—NRAS—gallbladder cancer	0.00308	0.00308	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—KRAS—gallbladder cancer	0.00307	0.00307	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—ERBB2—gallbladder cancer	0.00306	0.00306	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—EGFR—gallbladder cancer	0.00301	0.00301	CbGpPWpGaD
Temsirolimus—MTOR—Leptin signaling pathway—HRAS—gallbladder cancer	0.00299	0.00299	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—KRAS—gallbladder cancer	0.00299	0.00299	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—KRAS—gallbladder cancer	0.00299	0.00299	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	0.00296	0.00296	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—ERBB3—gallbladder cancer	0.00294	0.00294	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—EGFR—gallbladder cancer	0.00294	0.00294	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—ERBB2—gallbladder cancer	0.00292	0.00292	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—EGFR—gallbladder cancer	0.00291	0.00291	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—NRAS—gallbladder cancer	0.00291	0.00291	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—ERBB2—gallbladder cancer	0.0029	0.0029	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—ERBB2—gallbladder cancer	0.0029	0.0029	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—ERBB2—gallbladder cancer	0.00289	0.00289	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—NRAS—gallbladder cancer	0.00289	0.00289	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—ERBB2—gallbladder cancer	0.00288	0.00288	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—gallbladder cancer	0.00285	0.00285	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—EGFR—gallbladder cancer	0.00285	0.00285	CbGpPWpGaD
Temsirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—gallbladder cancer	0.00284	0.00284	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—gallbladder cancer	0.00283	0.00283	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—HRAS—gallbladder cancer	0.00271	0.00271	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—gallbladder cancer	0.00271	0.00271	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—ERBB2—gallbladder cancer	0.00271	0.00271	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—ERBB2—gallbladder cancer	0.00271	0.00271	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—KRAS—gallbladder cancer	0.00269	0.00269	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—ERBB2—gallbladder cancer	0.00268	0.00268	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—gallbladder cancer	0.00266	0.00266	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—gallbladder cancer	0.00265	0.00265	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—ERBB2—gallbladder cancer	0.00265	0.00265	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	0.00263	0.00263	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—HRAS—gallbladder cancer	0.00263	0.00263	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—gallbladder cancer	0.00261	0.00261	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—HRAS—gallbladder cancer	0.00254	0.00254	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—HRAS—gallbladder cancer	0.00254	0.00254	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—ERBB2—gallbladder cancer	0.0025	0.0025	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—KRAS—gallbladder cancer	0.0025	0.0025	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—KRAS—gallbladder cancer	0.00248	0.00248	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—NRAS—gallbladder cancer	0.00247	0.00247	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—gallbladder cancer	0.0024	0.0024	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—gallbladder cancer	0.00239	0.00239	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KEAP1—gallbladder cancer	0.00238	0.00238	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—NRAS—gallbladder cancer	0.00236	0.00236	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—NRAS—gallbladder cancer	0.00232	0.00232	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—HRAS—gallbladder cancer	0.00229	0.00229	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—gallbladder cancer	0.00229	0.00229	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—gallbladder cancer	0.00225	0.00225	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—EGFR—gallbladder cancer	0.00225	0.00225	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—NRAS—gallbladder cancer	0.00222	0.00222	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—NRAS—gallbladder cancer	0.00221	0.00221	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—NRAS—gallbladder cancer	0.0022	0.0022	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—NRAS—gallbladder cancer	0.00219	0.00219	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—gallbladder cancer	0.00216	0.00216	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—gallbladder cancer	0.00215	0.00215	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—gallbladder cancer	0.00213	0.00213	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—HRAS—gallbladder cancer	0.00213	0.00213	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—KRAS—gallbladder cancer	0.00212	0.00212	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—EGFR—gallbladder cancer	0.00212	0.00212	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—HRAS—gallbladder cancer	0.00211	0.00211	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—NRAS—gallbladder cancer	0.00206	0.00206	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—gallbladder cancer	0.00206	0.00206	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—NRAS—gallbladder cancer	0.00206	0.00206	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—NRAS—gallbladder cancer	0.00204	0.00204	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—KRAS—gallbladder cancer	0.00203	0.00203	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—EGFR—gallbladder cancer	0.00202	0.00202	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—NRAS—gallbladder cancer	0.00202	0.00202	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—EGFR—gallbladder cancer	0.00201	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—gallbladder cancer	0.00201	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—NRAS—gallbladder cancer	0.00201	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—gallbladder cancer	0.00201	0.00201	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—EGFR—gallbladder cancer	0.002	0.002	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—KRAS—gallbladder cancer	0.002	0.002	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—EGFR—gallbladder cancer	0.00199	0.00199	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—gallbladder cancer	0.00196	0.00196	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—ERBB4—gallbladder cancer	0.00194	0.00194	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—KRAS—gallbladder cancer	0.00191	0.00191	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—NRAS—gallbladder cancer	0.0019	0.0019	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—KRAS—gallbladder cancer	0.0019	0.0019	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—gallbladder cancer	0.0019	0.0019	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—KRAS—gallbladder cancer	0.00189	0.00189	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—KRAS—gallbladder cancer	0.00188	0.00188	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—EGFR—gallbladder cancer	0.00188	0.00188	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—EGFR—gallbladder cancer	0.00188	0.00188	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—gallbladder cancer	0.00188	0.00188	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ERBB4—gallbladder cancer	0.00186	0.00186	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—EGFR—gallbladder cancer	0.00186	0.00186	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—gallbladder cancer	0.00186	0.00186	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ERBB4—gallbladder cancer	0.00185	0.00185	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—ERBB2—gallbladder cancer	0.00184	0.00184	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—gallbladder cancer	0.00184	0.00184	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—EGFR—gallbladder cancer	0.00183	0.00183	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—gallbladder cancer	0.00182	0.00182	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—HRAS—gallbladder cancer	0.00181	0.00181	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—gallbladder cancer	0.00179	0.00179	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—HRAS—gallbladder cancer	0.00178	0.00178	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—KRAS—gallbladder cancer	0.00177	0.00177	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—KRAS—gallbladder cancer	0.00177	0.00177	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—gallbladder cancer	0.00177	0.00177	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—KRAS—gallbladder cancer	0.00176	0.00176	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—KRAS—gallbladder cancer	0.00174	0.00174	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—EGFR—gallbladder cancer	0.00174	0.00174	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—KRAS—gallbladder cancer	0.00173	0.00173	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—gallbladder cancer	0.00173	0.00173	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—HRAS—gallbladder cancer	0.0017	0.0017	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—ERBB3—gallbladder cancer	0.00168	0.00168	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—gallbladder cancer	0.00166	0.00166	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—KRAS—gallbladder cancer	0.00164	0.00164	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—HRAS—gallbladder cancer	0.00163	0.00163	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—HRAS—gallbladder cancer	0.00162	0.00162	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—HRAS—gallbladder cancer	0.00162	0.00162	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—gallbladder cancer	0.00162	0.00162	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ERBB3—gallbladder cancer	0.00161	0.00161	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—HRAS—gallbladder cancer	0.00161	0.00161	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ERBB3—gallbladder cancer	0.0016	0.0016	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—HRAS—gallbladder cancer	0.0016	0.0016	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	0.00158	0.00158	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—gallbladder cancer	0.00157	0.00157	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—gallbladder cancer	0.00151	0.00151	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—HRAS—gallbladder cancer	0.00151	0.00151	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—HRAS—gallbladder cancer	0.00151	0.00151	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—HRAS—gallbladder cancer	0.00149	0.00149	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—gallbladder cancer	0.00148	0.00148	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—HRAS—gallbladder cancer	0.00147	0.00147	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—NRAS—gallbladder cancer	0.0014	0.0014	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—HRAS—gallbladder cancer	0.00139	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—gallbladder cancer	0.00133	0.00133	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ERBB4—gallbladder cancer	0.0013	0.0013	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—EGFR—gallbladder cancer	0.00128	0.00128	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—KRAS—gallbladder cancer	0.00121	0.00121	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—gallbladder cancer	0.00114	0.00114	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ERBB4—gallbladder cancer	0.00113	0.00113	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—gallbladder cancer	0.00113	0.00113	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ERBB3—gallbladder cancer	0.00112	0.00112	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—gallbladder cancer	0.0011	0.0011	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—BCL2—gallbladder cancer	0.00108	0.00108	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—ERBB2—gallbladder cancer	0.00105	0.00105	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB4—gallbladder cancer	0.00104	0.00104	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—HRAS—gallbladder cancer	0.00103	0.00103	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ERBB2—gallbladder cancer	0.00101	0.00101	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ERBB2—gallbladder cancer	0.00101	0.00101	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ERBB3—gallbladder cancer	0.000976	0.000976	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB3—gallbladder cancer	0.000902	0.000902	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—NRAS—gallbladder cancer	0.0008	0.0008	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—NRAS—gallbladder cancer	0.000768	0.000768	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NRAS—gallbladder cancer	0.000765	0.000765	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	0.00076	0.00076	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB4—gallbladder cancer	0.00073	0.00073	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EGFR—gallbladder cancer	0.000729	0.000729	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	0.000718	0.000718	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ERBB2—gallbladder cancer	0.000704	0.000704	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—EGFR—gallbladder cancer	0.0007	0.0007	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EGFR—gallbladder cancer	0.000697	0.000697	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KRAS—gallbladder cancer	0.000688	0.000688	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KRAS—gallbladder cancer	0.000661	0.000661	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KRAS—gallbladder cancer	0.000658	0.000658	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	0.000638	0.000638	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB3—gallbladder cancer	0.000631	0.000631	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—BCL2—gallbladder cancer	0.00063	0.00063	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ERBB2—gallbladder cancer	0.000612	0.000612	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—gallbladder cancer	0.000585	0.000585	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB2—gallbladder cancer	0.000565	0.000565	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—gallbladder cancer	0.000562	0.000562	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—gallbladder cancer	0.000559	0.000559	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NRAS—gallbladder cancer	0.000535	0.000535	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—gallbladder cancer	0.000488	0.000488	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NRAS—gallbladder cancer	0.000466	0.000466	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—gallbladder cancer	0.000461	0.000461	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NRAS—gallbladder cancer	0.00043	0.00043	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—gallbladder cancer	0.000424	0.000424	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—gallbladder cancer	0.00041	0.00041	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—gallbladder cancer	0.000401	0.000401	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB2—gallbladder cancer	0.000396	0.000396	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—gallbladder cancer	0.000392	0.000392	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—gallbladder cancer	0.000392	0.000392	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—gallbladder cancer	0.00037	0.00037	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—gallbladder cancer	0.000341	0.000341	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—gallbladder cancer	0.000315	0.000315	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NRAS—gallbladder cancer	0.000301	0.000301	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—gallbladder cancer	0.000274	0.000274	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—gallbladder cancer	0.000259	0.000259	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—gallbladder cancer	0.00023	0.00023	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—gallbladder cancer	0.00022	0.00022	CbGpPWpGaD
